Back to top
more

Apellis Pharmaceuticals (APLS)

(Delayed Data from NSDQ)

$28.83 USD

28.83
3,842,937

+0.76 (2.69%)

Updated Nov 6, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Apellis (APLS) Expands Deal for Targeted Complement Therapies

by Zacks Equity Research

Apellis (APLS) expands its current research and development deal with privately held company, Affilogic, to develop targeted complement therapies for delivery into the brain.

Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease

by Zacks Equity Research

Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.

Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 4.5% Since Last Earnings Report?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy

by Zacks Equity Research

Apellis (APLS) submits a new drug application to the FDA for pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.

Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top

by Zacks Equity Research

Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.

    Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -4.41% and 12.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe

    by Zacks Equity Research

    Apellis' (APLS) marketed drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.

      Why Is Apellis Pharmaceuticals, Inc. (APLS) Up 8.9% Since Last Earnings Report?

      by Zacks Equity Research

      Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development

      by Zacks Equity Research

      Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.

      Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates

      by Zacks Equity Research

      Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.

      Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -21.97% and 607.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

      Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Travere (TVTX) delivered earnings and revenue surprises of -16.67% and 1.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

      Kinjel Shah headshot

      5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

      by Kinjel Shah

      Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

      Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

      by Zacks Equity Research

      On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.

      Why Apellis (APLS) Might Surprise This Earnings Season

      by Zacks Equity Research

      Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      Avid (CDMO) to Report Q3 Earnings: What's in the Cards?

      by Zacks Equity Research

      Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.

        Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

        by Zacks Equity Research

        Apellis Pharmaceuticals, Inc. (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

        NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug

        by Zacks Equity Research

        The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.

        Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why

        by Zacks Equity Research

        Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.

        Apellis (APLS), Sobi Get EU Nod for Rare Blood Disorder Drug

        by Zacks Equity Research

        The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.

        Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates

        by Zacks Equity Research

        Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.

        Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -31.79% and 143.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

        Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

        by Zacks Equity Research

        Apellis Pharmaceuticals, Inc. (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

        Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)

        by Zacks Equity Research

        The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.